Pfizer Inc. (NYSE:PFE) Given Average Rating of “Hold” by Brokerages

Pfizer Inc. (NYSE:PFE) has been given a consensus rating of “Hold” by the twenty-one research firms that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $28.2778.

Several analysts recently commented on the company. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. UBS Group restated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research report on Wednesday, May 27th. Guggenheim dropped their price objective on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Monday, July 6th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, July 8th.

Pfizer Stock Performance

PFE stock opened at $28.57 on Wednesday. Pfizer has a one year low of $23.58 and a one year high of $29.09. The firm has a market cap of $162.84 billion, a price-to-earnings ratio of 37.59 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The firm has a 50-day simple moving average of $25.69 and a two-hundred day simple moving average of $26.31.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the firm earned $0.78 earnings per share. The company’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts forecast that Pfizer will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were given a dividend of $0.43 per share. The ex-dividend date was Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.0%. Pfizer’s dividend payout ratio is currently 226.32%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Strong quarterly results supported the move higher. Pfizer’s second-quarter earnings and revenue exceeded analyst expectations, while full-year 2026 EPS guidance remains $2.80–$3.00. The results suggest resilience despite comparisons with the prior year’s COVID-related performance. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Depo-Provera litigation uncertainty has been reduced. Pfizer reached a confidential settlement covering more than 6,000 federal lawsuits alleging a connection between Depo-Provera and intracranial meningioma. Although the financial terms were not disclosed and Pfizer admitted no liability, the agreement removes a significant legal overhang. Pfizer Reaches Confidential Settlement in Depo-Provera Litigation
• Positive Sentiment: Investors are focusing on oncology growth. Padcev, pipeline programs such as PF-08634404 and potential label expansions are central to Pfizer’s effort to offset declining COVID product sales and build longer-term growth. Pfizer’s Oncology Growth Push
• Positive Sentiment: Higher EPS estimates and dividend appeal may be supporting demand. Erste Group Bank increased its FY2026 EPS estimate, while Pfizer’s relatively high dividend yield may attract income-oriented investors seeking defensive healthcare exposure. Pfizer FY2026 EPS Estimate Increased by Erste Group Bank
• Neutral Sentiment: Analysts remain moderately optimistic, but Pfizer has underperformed the S&P 500 over the past year, underscoring continuing concerns about growth and execution. Is Pfizer Stock Underperforming the S&P 500?
• Negative Sentiment: Unusual options activity included purchases of 147,173 put options, about 24% above average. This may reflect bearish positioning or hedging and signals that some traders remain cautious despite the recent rally.

Hedge Funds Weigh In On Pfizer

A number of hedge funds have recently made changes to their positions in the company. Godfrey Financial Associates Inc. acquired a new position in shares of Pfizer during the 4th quarter valued at about $26,000. Keb Asset Management LLC acquired a new stake in Pfizer during the second quarter worth about $26,000. Field & Main Bank acquired a new position in Pfizer in the 2nd quarter valued at about $27,000. HFM Investment Advisors LLC boosted its holdings in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the last quarter. Finally, Evolution Wealth Management Inc. grew its stake in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 566 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.